Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with a number of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health.
Fractyl Health, based in Lexington, Massachusetts, specializes in developing innovative medical device solutions for metabolic diseases, particularly type 2 diabetes and obesity. The company’s primary offering, Revita DMR, is a minimally invasive therapy that utilizes hydrothermal ablation to rejuvenate the duodenal lining, which can become compromised due to high-fat and high-sugar diets. By focusing on durable disease-modifying therapies rather than just symptomatic management, Fractyl Health aims to address the underlying causes of metabolic diseases, improving patient outcomes and reducing healthcare burdens. Founded in 2010 and originally named MedCatalyst, Inc., the company envisions a future where less invasive, device-based therapies provide effective solutions for large populations affected by metabolic disorders.
Axial Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system diseases and disorders. Based in Waltham, Massachusetts, the company utilizes a microbiome discovery platform that targets the gut-brain axis, allowing for the exploration and creation of innovative therapies aimed at improving the quality of life for patients suffering from neurological conditions. Incorporated in 2013, Axial Biotherapeutics seeks to advance its pipeline of novel treatments to address the unmet needs in the field of CNS disorders.
Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections. Antios Therapeutics was founded by Abel De La Rosa, Douglas Mayers, and Idean Marvasty.
Nobias Therapeutics is a biotechnology company dedicated to developing treatments for genetically-defined rare pediatric diseases. The company emphasizes the discovery of the genetic underpinnings of these conditions and aims to create drugs that target the affected biological pathways, ultimately improving health outcomes for children. By integrating artificial intelligence and machine learning with genetic and tissue databases, Nobias Therapeutics streamlines the drug discovery process, automating and simulating extensive pre-clinical and discovery phases. This innovative approach enables researchers to identify and develop new medicines, diagnostics, and insights for rare diseases, offering hope to families dealing with these challenging health issues.
Exalys Therapeutics is engaged in the development of innovative anti-inflammatory therapeutics aimed at addressing a variety of diseases that currently have significant unmet medical needs. The company is focusing on creating first-in-class therapies, with an initial emphasis on preventing postoperative delirium, a common complication among older surgical patients that can lead to adverse health outcomes. By targeting inflammatory disorders, including pain and renal dysfunction, Exalys aims to provide effective treatment options for conditions that are often serious and life-threatening, yet lack adequate therapies.
Seraphina Therapeutics, Inc. is a health and wellness company based in San Diego, California, focused on developing therapeutic solutions aimed at treating the comorbidities of aging and slowing the aging process. Founded in 2017, the company offers a range of products, including fatty acid supplements, micronutrients, food fortifiers, and nutritional interventions. These evidence-driven consumer products are designed to enhance cellular health, support mitochondrial function, and promote cellular homeostasis, ultimately helping individuals improve mood, manage caloric intake, and boost fat metabolism. By advancing nature and food-based science, Seraphina Therapeutics aims to contribute to healthier, longer lives.
Aspen Neuroscience, Inc. is a biotechnology company focused on developing induced pluripotent stem cells (iPSCs) to create patient-specific therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018 and based in San Diego, California, the company is advancing its pipeline of products, which includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited autologous neuron replacement therapy targeting familial forms of the disease. Aspen Neuroscience employs innovative genomic approaches in conjunction with stem cell biology to address diseases with significant unmet medical needs, aiming to provide restorative cell therapies that can modify the progression of Parkinson's disease and potentially extend to other affected organs.
Omniome, Inc. is a biotechnology company based in San Diego, California, focused on developing a DNA sequencing platform that aims to deliver high accuracy in clinical sequencing. Founded in 2013, the company utilizes its proprietary Sequencing By Binding technology, which enhances nucleotide and DNA matching by harnessing the natural capabilities of polymerase. This innovative approach allows researchers to obtain accurate and rapid sequencing results at a lower cost, with the potential to significantly advance cancer diagnostics. Omniome is supported by prominent life sciences venture investors and is committed to becoming a trusted leader in the field of DNA sequencing.
ChromaCode, Inc. is a molecular diagnostics company based in Carlsbad, California, founded in 2012. The company specializes in developing innovative testing solutions for infectious diseases, cancer, and non-invasive prenatal testing (NIPT) by utilizing patented mathematical methods and algorithmic enhancements. ChromaCode's products significantly enhance the multiplexing capabilities of quantitative polymerase chain reaction (qPCR) instruments, allowing laboratories to perform cost-effective testing of multiple targets from a single sample. Their offerings include software, reagents, and assays that improve signal processing and overall assay performance, making diagnostics more accessible and efficient. Among their notable products is the HDPCR Tick-Borne Pathogen Panel, a multiplex test that detects various tick-borne pathogens in one assay.
Aspen Neuroscience, Inc. is a biotechnology company focused on developing induced pluripotent stem cells (iPSCs) to create patient-specific therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018 and based in San Diego, California, the company is advancing its pipeline of products, which includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited autologous neuron replacement therapy targeting familial forms of the disease. Aspen Neuroscience employs innovative genomic approaches in conjunction with stem cell biology to address diseases with significant unmet medical needs, aiming to provide restorative cell therapies that can modify the progression of Parkinson's disease and potentially extend to other affected organs.
Truvian Sciences Inc, based in San Diego, California, specializes in developing automated diagnostic equipment that transforms the blood testing industry. Founded in 2015, the company offers a benchtop system designed to deliver lab-accurate results for a range of health tests. Its comprehensive wellness panel includes commonly ordered routine blood tests such as complete blood count, metabolic panel, and lipid panel, all processed from a single sample. Additionally, Truvian Sciences provides a software platform that enables healthcare practitioners to efficiently share test data with patients.
Axial Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system diseases and disorders. Based in Waltham, Massachusetts, the company utilizes a microbiome discovery platform that targets the gut-brain axis, allowing for the exploration and creation of innovative therapies aimed at improving the quality of life for patients suffering from neurological conditions. Incorporated in 2013, Axial Biotherapeutics seeks to advance its pipeline of novel treatments to address the unmet needs in the field of CNS disorders.
Singular Genomics is a life science technology company focused on advancing next generation sequencing (NGS) and multiomics technologies to support researchers and clinicians. The company's core platform, the Singular Sequencing Engine, underpins its product offerings, emphasizing accuracy, speed, flexibility, and scalability. Singular Genomics has developed two primary integrated solutions: the G4 Integrated Solution, which targets the NGS market with a combination of instrument and consumable kits, and the PX Integrated Solution, which integrates single cell analysis, spatial analysis, genomics, and proteomics into a versatile platform. These solutions cater to various market segments, including basic biology, oncology, and immunology, enhancing research capabilities across diverse applications.
Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections. Antios Therapeutics was founded by Abel De La Rosa, Douglas Mayers, and Idean Marvasty.
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, focused on developing and commercializing etripamil for various cardiovascular conditions. Etripamil is a novel short-acting calcium channel blocker designed to be administered as a rapid-onset nasal spray, specifically targeting the termination of episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently conducting Phase III clinical trials for etripamil in the treatment of PSVT and is also exploring its potential applications for atrial fibrillation, angina, and other related cardiovascular disorders. Founded in 2003, Milestone Pharmaceuticals aims to address unmet medical needs in cardiovascular disease management through innovative therapeutic solutions.
Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with a number of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health.
Omniome, Inc. is a biotechnology company based in San Diego, California, focused on developing a DNA sequencing platform that aims to deliver high accuracy in clinical sequencing. Founded in 2013, the company utilizes its proprietary Sequencing By Binding technology, which enhances nucleotide and DNA matching by harnessing the natural capabilities of polymerase. This innovative approach allows researchers to obtain accurate and rapid sequencing results at a lower cost, with the potential to significantly advance cancer diagnostics. Omniome is supported by prominent life sciences venture investors and is committed to becoming a trusted leader in the field of DNA sequencing.
WindMIL Therapeutics, Inc. is a biotechnology company founded in 2015 and headquartered in Princeton, New Jersey. It focuses on developing innovative cell therapies for cancer patients by translating insights from bone marrow immunology. The company specializes in a novel class of therapies known as Marrow Infiltrating Lymphocytes (MILs), which are derived from memory T cells found in the bone marrow. By reactivating dormant T-cells and utilizing bone marrow-derived lymphocytes, WindMIL Therapeutics aims to create effective immunotherapies that harness the unique properties of the bone marrow, ultimately improving treatment options for oncology patients.
Celtaxsys, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for inflammatory diseases, cancer, and autoimmune disorders. Established in 2007 and headquartered in Atlanta, Georgia, the company is engaged in developing drug compounds that manipulate immune cell migration and activation. One of its key products, CTX-4430, is a small-molecule drug designed to inhibit the enzyme Leukotriene A4 hydrolase in immune cells, targeting conditions such as cystic fibrosis and moderately severe acne. Celtaxsys aims to provide innovative treatments that address the protective mechanisms of certain tumors, thereby enhancing the immune response against cancer and managing serious inflammatory conditions.
Fractyl Health, based in Lexington, Massachusetts, specializes in developing innovative medical device solutions for metabolic diseases, particularly type 2 diabetes and obesity. The company’s primary offering, Revita DMR, is a minimally invasive therapy that utilizes hydrothermal ablation to rejuvenate the duodenal lining, which can become compromised due to high-fat and high-sugar diets. By focusing on durable disease-modifying therapies rather than just symptomatic management, Fractyl Health aims to address the underlying causes of metabolic diseases, improving patient outcomes and reducing healthcare burdens. Founded in 2010 and originally named MedCatalyst, Inc., the company envisions a future where less invasive, device-based therapies provide effective solutions for large populations affected by metabolic disorders.
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, focused on developing and commercializing etripamil for various cardiovascular conditions. Etripamil is a novel short-acting calcium channel blocker designed to be administered as a rapid-onset nasal spray, specifically targeting the termination of episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently conducting Phase III clinical trials for etripamil in the treatment of PSVT and is also exploring its potential applications for atrial fibrillation, angina, and other related cardiovascular disorders. Founded in 2003, Milestone Pharmaceuticals aims to address unmet medical needs in cardiovascular disease management through innovative therapeutic solutions.
Sebacia, Inc. is a private medical device company dedicated to creating breakthrough topical therapies for the treatment of dermatological conditions affecting millions of people. Sebacia's goal is to provide a better alternative to the daily use of topical and systemic drugs currently available for the treatment of acne. Sebacia's patented microparticles technology was invented at Rice University, and the proprietary dermatology applications were further developed with researchers from the Wellman Center of Photomedicine at Massachusetts General Hospital. Sebacia is located in Duluth, Georgia.
Iterum Therapeutics plc is a clinical-stage pharmaceutical company focused on developing anti-infective therapies to address multi-drug resistant pathogens. Headquartered in Dublin, Ireland, the company is advancing its lead product, sulopenem, a novel penem compound available in both oral and intravenous formulations. Currently in Phase III clinical trials, sulopenem is being evaluated for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum aims to provide effective solutions to combat antibiotic resistance, particularly against a range of gram-negative, gram-positive, and anaerobic bacteria that are resistant to existing antibiotics. Founded in 2015, Iterum Therapeutics seeks to improve the lives of patients affected by serious and life-threatening infections globally.
Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with a number of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health.
ChromaCode, Inc. is a molecular diagnostics company based in Carlsbad, California, founded in 2012. The company specializes in developing innovative testing solutions for infectious diseases, cancer, and non-invasive prenatal testing (NIPT) by utilizing patented mathematical methods and algorithmic enhancements. ChromaCode's products significantly enhance the multiplexing capabilities of quantitative polymerase chain reaction (qPCR) instruments, allowing laboratories to perform cost-effective testing of multiple targets from a single sample. Their offerings include software, reagents, and assays that improve signal processing and overall assay performance, making diagnostics more accessible and efficient. Among their notable products is the HDPCR Tick-Borne Pathogen Panel, a multiplex test that detects various tick-borne pathogens in one assay.
Dicerna Pharmaceuticals is a biotechnology company dedicated to the discovery and development of innovative treatments for rare inherited diseases and other conditions affecting the liver. Utilizing its proprietary ribonucleic acid interference (RNAi) technology, specifically the GalXC platform, Dicerna focuses on silencing disease-causing genes to develop pharmaceuticals for various therapeutic areas, including liver diseases, cardiovascular diseases, and cancers. Key product candidates include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, and additional programs targeting undisclosed rare liver diseases. The company has established strategic collaborations with several major pharmaceutical firms to enhance its research and development efforts. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna Pharmaceuticals aims to address significant unmet medical needs through its innovative approaches.
Adynxx is a clinical-stage biopharmaceutical company based in San Francisco, California, focused on developing innovative pain management therapies. Established in 2007, the company is working on a new class of therapeutics known as transcription factor decoys to address unmet medical needs in pain and inflammation treatment. Its pipeline features AYX1, a drug candidate aimed at preventing acute post-operative pain and its progression to chronic pain, and brivoligide, currently in Phase 2 trials for postoperative pain management. Additionally, Adynxx is developing AYX2, a pre-clinical candidate designed to treat chronic pain syndromes, including inflammatory and neuropathic pain.
Axial Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system diseases and disorders. Based in Waltham, Massachusetts, the company utilizes a microbiome discovery platform that targets the gut-brain axis, allowing for the exploration and creation of innovative therapies aimed at improving the quality of life for patients suffering from neurological conditions. Incorporated in 2013, Axial Biotherapeutics seeks to advance its pipeline of novel treatments to address the unmet needs in the field of CNS disorders.
Axial Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system diseases and disorders. Based in Waltham, Massachusetts, the company utilizes a microbiome discovery platform that targets the gut-brain axis, allowing for the exploration and creation of innovative therapies aimed at improving the quality of life for patients suffering from neurological conditions. Incorporated in 2013, Axial Biotherapeutics seeks to advance its pipeline of novel treatments to address the unmet needs in the field of CNS disorders.
Gene Sciences operates as a biotech company. The company serves customers in the United States. Gene Sciences is committed to developing novel DNA targeted therapeutics that modulate gene expression for the treatment of human disease.
ReVision Optics, Inc. is a company based in Lake Forest, California, specializing in the design, manufacture, and delivery of implantable products aimed at treating presbyopia, a condition that affects near vision due to aging. The company offers the PRESBYLENS Corneal Inlay, a patented refractive surgery solution that enhances near vision for patients experiencing this common age-related vision loss. By providing innovative optical technology, ReVision Optics enables ophthalmology professionals to deliver improved eyesight solutions to their patients. Founded in 1996 and originally named IntraLens Vision, Inc., the company rebranded in 2005 to align with its focus on presbyopia treatments.
ROX Medical is an early phase medical device company that is pioneering an innovative treatment for Chronic Obstructive Pulmonary Disease (COPD). Their therapy is intended to improve the delivery of oxygen to tissue to treat hypoxemia in COPD patients via the creation of a therapeutic fistula.
Bionano Genomics is a biotechnology company that specializes in genome mapping and analysis, focusing on structural variation detection in DNA. The company develops the Saphyr system, which offers ultra-sensitive and specific detection of structural variations—such as insertions, deletions, inversions, and translocations—linked to various genetic disorders, including cancer. Utilizing optical genome mapping technology, the Saphyr system enables the direct visualization of long DNA molecules and their structural variations without the need for sequencing. This capability is crucial for researchers and clinicians aiming to gain insights into disease mechanisms and genetic disorders, ultimately aiding in the development of personalized treatment strategies. Bionano Genomics markets its products primarily to academic and governmental laboratories, as well as pharmaceutical and biotechnology companies across multiple regions, including North America, Europe, and Asia. Headquartered in San Diego, California, the company was founded in 2003 and was previously known as BioNano Genomics, Inc. until its name change in July 2018.
Miramar Labs is a company based in Sunnyvale, California, that specializes in developing medical devices for aesthetic purposes, particularly focusing on the treatment of primary axillary hyperhidrosis in adults. Founded in 2006, the company offers the miraDry System, which provides a non-invasive solution for excessive sweating and odor. This system employs microwave energy to selectively target and permanently eliminate sweat and odor glands in the underarm area. By addressing these concerns, Miramar Labs aims to enhance the confidence and quality of life for individuals suffering from this condition. However, the miraDry System is not designed to treat hyperhidrosis in other areas of the body, such as the hands and feet.
Obalon Therapeutics, Inc. is a medical device company based in Carlsbad, California, that specializes in developing and commercializing innovative solutions for obesity treatment. The company is known for its Obalon Balloon System, which includes a swallowable capsule containing an inflatable balloon, a navigation console for tracking balloon placement, a semi-automated inflation device, and a disposable gas canister. This system aims to assist patients in achieving weight loss through a non-surgical approach. Founded in 2008, Obalon emphasizes collaboration with clinicians and a commitment to rigorous testing to ensure safety and performance in its products. As of early 2020, the company operated three retail treatment centers in California, reflecting its focus on providing accessible solutions for individuals struggling with obesity.
Bionano Genomics is a biotechnology company that specializes in genome mapping and analysis, focusing on structural variation detection in DNA. The company develops the Saphyr system, which offers ultra-sensitive and specific detection of structural variations—such as insertions, deletions, inversions, and translocations—linked to various genetic disorders, including cancer. Utilizing optical genome mapping technology, the Saphyr system enables the direct visualization of long DNA molecules and their structural variations without the need for sequencing. This capability is crucial for researchers and clinicians aiming to gain insights into disease mechanisms and genetic disorders, ultimately aiding in the development of personalized treatment strategies. Bionano Genomics markets its products primarily to academic and governmental laboratories, as well as pharmaceutical and biotechnology companies across multiple regions, including North America, Europe, and Asia. Headquartered in San Diego, California, the company was founded in 2003 and was previously known as BioNano Genomics, Inc. until its name change in July 2018.
Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, particularly vertebral compression fractures and degenerative disc diseases. Its key products include the Kiva treatment system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for pathological vertebral compression fractures. Additionally, the company offers the Luna 3D expandable interbody fusion system, suitable for various surgical approaches. Headquartered in Santa Clara, California, Benvenue Medical serves customers across the United States, Canada, Belgium, France, and Germany. Founded in 2004, the company is committed to providing innovative solutions that enhance patient outcomes and restore spinal alignment.
Singular Genomics is a life science technology company focused on advancing next generation sequencing (NGS) and multiomics technologies to support researchers and clinicians. The company's core platform, the Singular Sequencing Engine, underpins its product offerings, emphasizing accuracy, speed, flexibility, and scalability. Singular Genomics has developed two primary integrated solutions: the G4 Integrated Solution, which targets the NGS market with a combination of instrument and consumable kits, and the PX Integrated Solution, which integrates single cell analysis, spatial analysis, genomics, and proteomics into a versatile platform. These solutions cater to various market segments, including basic biology, oncology, and immunology, enhancing research capabilities across diverse applications.
Fractyl Health, based in Lexington, Massachusetts, specializes in developing innovative medical device solutions for metabolic diseases, particularly type 2 diabetes and obesity. The company’s primary offering, Revita DMR, is a minimally invasive therapy that utilizes hydrothermal ablation to rejuvenate the duodenal lining, which can become compromised due to high-fat and high-sugar diets. By focusing on durable disease-modifying therapies rather than just symptomatic management, Fractyl Health aims to address the underlying causes of metabolic diseases, improving patient outcomes and reducing healthcare burdens. Founded in 2010 and originally named MedCatalyst, Inc., the company envisions a future where less invasive, device-based therapies provide effective solutions for large populations affected by metabolic disorders.
Kona Medical, Inc. is a medical technology company founded in 2009 and based in Issaquah, Washington. It specializes in the development of a non-invasive ultrasound-based therapy system aimed at treating hypertension, particularly in patients with drug-resistant hypertension. The company's flagship product, Surround Sound, utilizes ultrasound imaging to precisely guide the application of focused ultrasound energy for renal denervation, targeting the nerves connected to the kidneys to help regulate blood pressure. By offering a less invasive alternative to traditional treatments, Kona Medical seeks to address the health risks associated with high blood pressure while improving patient outcomes through advanced therapeutic techniques.
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focused on developing therapies for cancer treatment. The company's lead product, entinostat, is a class I HDAC inhibitor currently in Phase III clinical trials for advanced hormone receptor positive, HER2 negative breast cancer. Additionally, entinostat is being tested in combination with Keytruda and Tecentriq in Phase Ib/II trials for non-small cell lung cancer and metastatic breast cancer. Another significant candidate, SNDX-5613, is a selective inhibitor targeting the Menin-MLL interaction, undergoing Phase I/II trials for acute leukemias. The company is also developing SNDX-6352, a monoclonal antibody for chronic graft versus host disease, currently in Phase I/II trials. Syndax has established collaborations with major pharmaceutical companies and research organizations, enhancing its research and development capabilities. Founded in 2005, Syndax Pharmaceuticals aims to address critical needs in oncology through innovative therapeutic approaches.
Xagenic Inc., a Toronto, Canada-based molecular diagnostics company developing new technology for decentralized, rapid diagnostic testing, and a true point-of-care platform. Our aim is to enable on-demand, near-patient molecular testing, empowering clinicians in making treatment decisions for their patients at the time of the first consultation. This will dramatically improve patient care and reduce health care costs. Xagenic has adapted this technology to permit rapid, enzyme-free detection of nucleic acids from clinical samples. We are commercializing a simple and fully automated technology platform that will enable widespread decentralized diagnostic testing to be performed outside of clinical laboratories. Our team is developing infectious disease tests that will allow the detection of a variety of analytes in situations where rapid test turnaround will provide clinically actionable results.
Sebacia, Inc. is a private medical device company dedicated to creating breakthrough topical therapies for the treatment of dermatological conditions affecting millions of people. Sebacia's goal is to provide a better alternative to the daily use of topical and systemic drugs currently available for the treatment of acne. Sebacia's patented microparticles technology was invented at Rice University, and the proprietary dermatology applications were further developed with researchers from the Wellman Center of Photomedicine at Massachusetts General Hospital. Sebacia is located in Duluth, Georgia.
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, focused on developing and commercializing etripamil for various cardiovascular conditions. Etripamil is a novel short-acting calcium channel blocker designed to be administered as a rapid-onset nasal spray, specifically targeting the termination of episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently conducting Phase III clinical trials for etripamil in the treatment of PSVT and is also exploring its potential applications for atrial fibrillation, angina, and other related cardiovascular disorders. Founded in 2003, Milestone Pharmaceuticals aims to address unmet medical needs in cardiovascular disease management through innovative therapeutic solutions.
Celtaxsys, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for inflammatory diseases, cancer, and autoimmune disorders. Established in 2007 and headquartered in Atlanta, Georgia, the company is engaged in developing drug compounds that manipulate immune cell migration and activation. One of its key products, CTX-4430, is a small-molecule drug designed to inhibit the enzyme Leukotriene A4 hydrolase in immune cells, targeting conditions such as cystic fibrosis and moderately severe acne. Celtaxsys aims to provide innovative treatments that address the protective mechanisms of certain tumors, thereby enhancing the immune response against cancer and managing serious inflammatory conditions.
Twelve manufactures medical devices. It was formerly known as Foundry Newco XII, Inc. The company was incorporated in 2009 and is based in Menlo Park, California.
aTyr Pharma is a biotherapeutics company based in San Diego, California, specializing in the discovery and development of innovative medicines utilizing novel immunological pathways. The company focuses primarily on ATYR1923, a clinical-stage fusion protein designed to down-regulate immune engagement in interstitial lung diseases by binding to the neuropilin-2 receptor. This candidate is currently undergoing Phase 1b/2a clinical trials. aTyr Pharma has established a strong intellectual property portfolio centered around Physiocrine-based compositions and therapeutic applications, particularly in immunomodulation disorders related to inflammation and immunity. Additionally, the company has formed collaborations with several institutions, including the University of Nebraska Medical Center, CSL Behring, Boston Children’s Hospital, and the Medical University of South Carolina, to advance its research and development efforts. Founded in 2005 by a prominent scientist from The Scripps Research Institute, aTyr is supported by leading life sciences investors.
Obalon Therapeutics, Inc. is a medical device company based in Carlsbad, California, that specializes in developing and commercializing innovative solutions for obesity treatment. The company is known for its Obalon Balloon System, which includes a swallowable capsule containing an inflatable balloon, a navigation console for tracking balloon placement, a semi-automated inflation device, and a disposable gas canister. This system aims to assist patients in achieving weight loss through a non-surgical approach. Founded in 2008, Obalon emphasizes collaboration with clinicians and a commitment to rigorous testing to ensure safety and performance in its products. As of early 2020, the company operated three retail treatment centers in California, reflecting its focus on providing accessible solutions for individuals struggling with obesity.
CoLucid Pharmaceuticals, Inc., a biotechnology company, focuses on therapies for central nervous system disorders. The company develops COL-144, a neurally acting anti-migraine agent, which is designed to treat migraine; and COL-204, a conjugated stigmine platform that produces novel chemical entities for therapy of sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. CoLucid Pharmaceuticals was founded in 2005 and is based in Research Triangle Park, North Carolina.
Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, focused on developing diagnostic tests that assess a woman's individual risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other pregnancy-related complications. Founded in 2008, Sera aims to improve maternal and neonatal health while addressing the significant economic and healthcare burdens associated with premature birth. The company's proprietary proteomics and bioinformatics platform underpins its pipeline of innovative diagnostic tests, including the PreTRM® Test, which provides physicians with critical information to identify women at higher risk for spontaneous premature delivery. By enabling earlier proactive interventions, Sera seeks to enhance pregnancy care and reduce healthcare delivery costs.
Bionano Genomics is a biotechnology company that specializes in genome mapping and analysis, focusing on structural variation detection in DNA. The company develops the Saphyr system, which offers ultra-sensitive and specific detection of structural variations—such as insertions, deletions, inversions, and translocations—linked to various genetic disorders, including cancer. Utilizing optical genome mapping technology, the Saphyr system enables the direct visualization of long DNA molecules and their structural variations without the need for sequencing. This capability is crucial for researchers and clinicians aiming to gain insights into disease mechanisms and genetic disorders, ultimately aiding in the development of personalized treatment strategies. Bionano Genomics markets its products primarily to academic and governmental laboratories, as well as pharmaceutical and biotechnology companies across multiple regions, including North America, Europe, and Asia. Headquartered in San Diego, California, the company was founded in 2003 and was previously known as BioNano Genomics, Inc. until its name change in July 2018.
Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, focused on developing diagnostic tests that assess a woman's individual risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other pregnancy-related complications. Founded in 2008, Sera aims to improve maternal and neonatal health while addressing the significant economic and healthcare burdens associated with premature birth. The company's proprietary proteomics and bioinformatics platform underpins its pipeline of innovative diagnostic tests, including the PreTRM® Test, which provides physicians with critical information to identify women at higher risk for spontaneous premature delivery. By enabling earlier proactive interventions, Sera seeks to enhance pregnancy care and reduce healthcare delivery costs.
Miramar Labs is a company based in Sunnyvale, California, that specializes in developing medical devices for aesthetic purposes, particularly focusing on the treatment of primary axillary hyperhidrosis in adults. Founded in 2006, the company offers the miraDry System, which provides a non-invasive solution for excessive sweating and odor. This system employs microwave energy to selectively target and permanently eliminate sweat and odor glands in the underarm area. By addressing these concerns, Miramar Labs aims to enhance the confidence and quality of life for individuals suffering from this condition. However, the miraDry System is not designed to treat hyperhidrosis in other areas of the body, such as the hands and feet.
Zyga Technology, Inc. is a medical device company focused on developing and commercializing minimally invasive products for underserved conditions of the lumbar spine. The company offers the SImmetry Sacroiliac Joint Fusion System, which provides a surgical solution for sacroiliac joint fusion, addressing issues such as joint disruptions and degenerative sacroiliitis. Additionally, Zyga is working on the Glyder Facet Restoration System, an investigational device aimed at treating chronic facetogenic pain. Founded in 2008 and based in Minnetonka, Minnesota, Zyga Technology has assembled a skilled team with extensive experience in the spine industry. As of late 2017, Zyga operates as a subsidiary of RTI Surgical, Inc.
VentiRx Pharmaceuticals is a clinical stage biopharmaceutical company based in Seattle, Washington, focused on developing and commercializing immunotherapies targeting Toll-like Receptor 8 (TLR8) for the treatment of cancer, respiratory, and inflammatory diseases. Founded in 2006, the company’s lead investigational drug, Motolimod, works by mobilizing the patient's immune system to fight cancer through the activation of myeloid dendritic cells, monocytes, and natural killer cells. VentiRx's product pipeline includes VTX-2337, a TLR8 agonist aimed at enhancing immune responses against solid tumors and specific cancers such as ovarian and breast cancer, as well as VTX-1463, designed to address allergies. The company is also exploring TLR8 antagonists for autoimmune diseases and compounds intended as vaccine adjuvants. VentiRx Pharmaceuticals operates as a subsidiary of Celgene Corporation and has additional operations in San Diego.
Colorescience, Inc. is a skincare brand based in Carlsbad, California, specializing in mineral-based cosmetics and sunscreen products. Founded in 2000, the company offers a range of items, including treatment products, UV protectors, primers, foundations, and enhancers, designed to address various skin concerns such as pigmentation, redness, dark circles, and signs of aging. Colorescience emphasizes high-quality, dermatologist-recommended formulations that incorporate minerals, antioxidants, and botanicals to promote healthy skin and protect against sun damage. The brand markets its products through a network of licensed physicians, luxury spas, retailers, and online platforms, aiming to stand out in the aesthetic makeup segment by providing effective and easy-to-use solutions for diverse skin types.
Fractyl Health, based in Lexington, Massachusetts, specializes in developing innovative medical device solutions for metabolic diseases, particularly type 2 diabetes and obesity. The company’s primary offering, Revita DMR, is a minimally invasive therapy that utilizes hydrothermal ablation to rejuvenate the duodenal lining, which can become compromised due to high-fat and high-sugar diets. By focusing on durable disease-modifying therapies rather than just symptomatic management, Fractyl Health aims to address the underlying causes of metabolic diseases, improving patient outcomes and reducing healthcare burdens. Founded in 2010 and originally named MedCatalyst, Inc., the company envisions a future where less invasive, device-based therapies provide effective solutions for large populations affected by metabolic disorders.
Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with a number of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health.
Xagenic Inc., a Toronto, Canada-based molecular diagnostics company developing new technology for decentralized, rapid diagnostic testing, and a true point-of-care platform. Our aim is to enable on-demand, near-patient molecular testing, empowering clinicians in making treatment decisions for their patients at the time of the first consultation. This will dramatically improve patient care and reduce health care costs. Xagenic has adapted this technology to permit rapid, enzyme-free detection of nucleic acids from clinical samples. We are commercializing a simple and fully automated technology platform that will enable widespread decentralized diagnostic testing to be performed outside of clinical laboratories. Our team is developing infectious disease tests that will allow the detection of a variety of analytes in situations where rapid test turnaround will provide clinically actionable results.
Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, particularly vertebral compression fractures and degenerative disc diseases. Its key products include the Kiva treatment system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for pathological vertebral compression fractures. Additionally, the company offers the Luna 3D expandable interbody fusion system, suitable for various surgical approaches. Headquartered in Santa Clara, California, Benvenue Medical serves customers across the United States, Canada, Belgium, France, and Germany. Founded in 2004, the company is committed to providing innovative solutions that enhance patient outcomes and restore spinal alignment.
Otonomy, Inc. is a biopharmaceutical company based in San Diego, California, that specializes in developing therapeutics for ear disorders. The company markets OTIPRIO, a ciprofloxacin otic suspension used during tympanostomy tube placement surgery in pediatric patients. Otonomy is advancing several product candidates, including OTIVIDEX, a sustained-exposure formulation of dexamethasone for Ménière’s disease; OTO-313, a formulation for tinnitus in Phase I/II trials; and OTO-413, aimed at repairing cochlear synaptopathy and addressing speech-in-noise hearing difficulties. Additionally, the company is developing OTO-510, designed to prevent cisplatin-induced hearing loss, and OTO-6XX, which focuses on hair cell regeneration for severe hearing loss. Otonomy employs a proprietary formulation platform that enables sustained drug delivery from a single administration, enhancing treatment options for various ear-related conditions. The company also has strategic collaborations for gene therapy aimed at congenital hearing loss. Founded in 2008, Otonomy continues to lead advancements in otology through innovation and research.
Smart Medical Systems Ltd. is a company based in Ra’anana, Israel, specializing in the development, manufacturing, and commercialization of medical devices for gastroenterology and gastrointestinal endoscopy. The company offers a range of innovative products, including the G-EYE endoscope, which enhances polyp detection rates during colonoscopy through its unique Controlled Withdrawal technique. This approach improves visibility and facilitates easier, faster therapeutic interventions. Additionally, Smart Medical Systems has developed the NaviAid Platform and various balloon devices designed for ileoscopy and colonoscopy, as well as inflation systems that support these applications. The company aims to provide cost-effective solutions that enhance the practice of gastrointestinal endoscopy for both healthcare professionals and patients. It distributes its products through partners in the United States and Europe and is recognized for its commitment to quality, holding ISO 13485:2003 certification from European regulatory authorities.
Sequent Medical, Inc. is a medical device company focused on developing catheter-based neurovascular technologies. Founded in 2007 and headquartered in Aliso Viejo, California, with operations in Bonn, Germany, the company has created the proprietary Microbraid technology, which is integral to its WEB Aneurysm Embolization System. This system provides a versatile option for treating both ruptured and unruptured intracranial aneurysms and has received CE mark approval. The WEB device has been successfully used to treat nearly 600 aneurysms across Europe, Latin America, and New Zealand, although it is not available for sale or use in the United States. Sequent Medical, Inc. operates as a subsidiary of MicroVention, Inc.
Evofem Biosciences is a biopharmaceutical company focused on women's sexual and reproductive health. The company has developed Phexxi, a hormone-free vaginal gel that is the first of its kind approved in the United States for the prevention of pregnancy. Additionally, Evofem is working on EVO100, a vaginal pH regulator designed to prevent the transmission of Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. Headquartered in San Diego, California, Evofem aims to address unmet needs in the field of women’s health through innovative products.
Neothetics, Inc. was a clinical-stage specialty pharmaceutical company focused on developing therapeutics for the aesthetic market. Founded in 2007 and based in San Diego, California, the company aimed to address cosmetic concerns through innovative treatments. Its primary product candidate, LIPO-202, was an injectable formulation designed to reduce localized fat deposits, specifically targeting submental fat under the chin and central abdominal bulging in non-obese individuals. In January 2018, Neothetics was acquired by Evofem Biosciences in a reverse merger transaction, marking a significant shift in its business trajectory. The company was previously known as Lipothera, Inc. before rebranding in August 2014.
Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory, and manufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by the state-of-the-art Atara T-cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California. For additional information about the company, please visit atarabio.com.
Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory, and manufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by the state-of-the-art Atara T-cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California. For additional information about the company, please visit atarabio.com.
RightCare Solutions employs evidence-based technology to help healthcare providers optimize their discharge planning process. With their proprietary Discharge Decision Support System, D2S2, hospitals, insurers, and homecare agencies improve the quality of care for patients while alleviating the devastating toll that 30-day re-admissions exact on the healthcare system. It was founded in 2011 and headquartered in Horsham, Pennsylvania.
NovaDigm Therapeutics develops vaccines to protect patients from fungal and bacterial infections. Its products include NDV-3, a vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by fungal and bacterial pathogens; and Als3, an antigen vaccine, which provides protection against systemic and mucosal candidal infections. It was founded in 2005 and headquartered in Grand Forks, North Dakota.
Bionano Genomics is a biotechnology company that specializes in genome mapping and analysis, focusing on structural variation detection in DNA. The company develops the Saphyr system, which offers ultra-sensitive and specific detection of structural variations—such as insertions, deletions, inversions, and translocations—linked to various genetic disorders, including cancer. Utilizing optical genome mapping technology, the Saphyr system enables the direct visualization of long DNA molecules and their structural variations without the need for sequencing. This capability is crucial for researchers and clinicians aiming to gain insights into disease mechanisms and genetic disorders, ultimately aiding in the development of personalized treatment strategies. Bionano Genomics markets its products primarily to academic and governmental laboratories, as well as pharmaceutical and biotechnology companies across multiple regions, including North America, Europe, and Asia. Headquartered in San Diego, California, the company was founded in 2003 and was previously known as BioNano Genomics, Inc. until its name change in July 2018.
Otonomy, Inc. is a biopharmaceutical company based in San Diego, California, that specializes in developing therapeutics for ear disorders. The company markets OTIPRIO, a ciprofloxacin otic suspension used during tympanostomy tube placement surgery in pediatric patients. Otonomy is advancing several product candidates, including OTIVIDEX, a sustained-exposure formulation of dexamethasone for Ménière’s disease; OTO-313, a formulation for tinnitus in Phase I/II trials; and OTO-413, aimed at repairing cochlear synaptopathy and addressing speech-in-noise hearing difficulties. Additionally, the company is developing OTO-510, designed to prevent cisplatin-induced hearing loss, and OTO-6XX, which focuses on hair cell regeneration for severe hearing loss. Otonomy employs a proprietary formulation platform that enables sustained drug delivery from a single administration, enhancing treatment options for various ear-related conditions. The company also has strategic collaborations for gene therapy aimed at congenital hearing loss. Founded in 2008, Otonomy continues to lead advancements in otology through innovation and research.
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focused on developing therapies for cancer treatment. The company's lead product, entinostat, is a class I HDAC inhibitor currently in Phase III clinical trials for advanced hormone receptor positive, HER2 negative breast cancer. Additionally, entinostat is being tested in combination with Keytruda and Tecentriq in Phase Ib/II trials for non-small cell lung cancer and metastatic breast cancer. Another significant candidate, SNDX-5613, is a selective inhibitor targeting the Menin-MLL interaction, undergoing Phase I/II trials for acute leukemias. The company is also developing SNDX-6352, a monoclonal antibody for chronic graft versus host disease, currently in Phase I/II trials. Syndax has established collaborations with major pharmaceutical companies and research organizations, enhancing its research and development capabilities. Founded in 2005, Syndax Pharmaceuticals aims to address critical needs in oncology through innovative therapeutic approaches.
Applied Proteomics, Inc. is a diagnostics company based in San Diego, California, founded in 2006. The company specializes in developing noninvasive, blood-based tests aimed at monitoring and early detection of diseases through protein biomarkers. Its flagship product, the SimpliPro Colon test, exemplifies its approach to diagnostics. By leveraging a proteomics platform, Applied Proteomics focuses on creating innovative molecular diagnostic tools that facilitate the discovery of protein-based biomarkers. This technology enables healthcare providers to assess the proteome's current status, acting as an early-warning system for various diseases. The company's advancements in proteomics are directed toward enhancing personalized medicine and improving overall healthcare outcomes.
Dicerna Pharmaceuticals is a biotechnology company dedicated to the discovery and development of innovative treatments for rare inherited diseases and other conditions affecting the liver. Utilizing its proprietary ribonucleic acid interference (RNAi) technology, specifically the GalXC platform, Dicerna focuses on silencing disease-causing genes to develop pharmaceuticals for various therapeutic areas, including liver diseases, cardiovascular diseases, and cancers. Key product candidates include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, and additional programs targeting undisclosed rare liver diseases. The company has established strategic collaborations with several major pharmaceutical firms to enhance its research and development efforts. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna Pharmaceuticals aims to address significant unmet medical needs through its innovative approaches.
ReVision Optics, Inc. is a company based in Lake Forest, California, specializing in the design, manufacture, and delivery of implantable products aimed at treating presbyopia, a condition that affects near vision due to aging. The company offers the PRESBYLENS Corneal Inlay, a patented refractive surgery solution that enhances near vision for patients experiencing this common age-related vision loss. By providing innovative optical technology, ReVision Optics enables ophthalmology professionals to deliver improved eyesight solutions to their patients. Founded in 1996 and originally named IntraLens Vision, Inc., the company rebranded in 2005 to align with its focus on presbyopia treatments.
aTyr Pharma is a biotherapeutics company based in San Diego, California, specializing in the discovery and development of innovative medicines utilizing novel immunological pathways. The company focuses primarily on ATYR1923, a clinical-stage fusion protein designed to down-regulate immune engagement in interstitial lung diseases by binding to the neuropilin-2 receptor. This candidate is currently undergoing Phase 1b/2a clinical trials. aTyr Pharma has established a strong intellectual property portfolio centered around Physiocrine-based compositions and therapeutic applications, particularly in immunomodulation disorders related to inflammation and immunity. Additionally, the company has formed collaborations with several institutions, including the University of Nebraska Medical Center, CSL Behring, Boston Children’s Hospital, and the Medical University of South Carolina, to advance its research and development efforts. Founded in 2005 by a prominent scientist from The Scripps Research Institute, aTyr is supported by leading life sciences investors.
Veracyte, Inc. is a genomic diagnostics company based in South San Francisco, California, that specializes in improving patient care through advanced genomic testing. The company offers a range of diagnostic products, including the Afirma Genomic Sequencing Classifier for thyroid cancer, the Percepta Genomic Sequencing Classifier for lung cancer, the Envisia Genomic Classifier for idiopathic pulmonary fibrosis, and the Prosigna Breast Cancer Prognostic Gene Signature Assay. These tests help identify benign conditions, differentiate diseases, and assess cancer recurrence risk, thereby reducing the need for invasive procedures and expediting treatment decisions. Veracyte collaborates with various organizations, including Johnson & Johnson, to enhance the development and commercialization of innovative diagnostic tests. With a commitment to leveraging genomic science and technology, Veracyte aims to deliver effective solutions for patients and healthcare providers globally.
Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.
ReVision Optics, Inc. is a company based in Lake Forest, California, specializing in the design, manufacture, and delivery of implantable products aimed at treating presbyopia, a condition that affects near vision due to aging. The company offers the PRESBYLENS Corneal Inlay, a patented refractive surgery solution that enhances near vision for patients experiencing this common age-related vision loss. By providing innovative optical technology, ReVision Optics enables ophthalmology professionals to deliver improved eyesight solutions to their patients. Founded in 1996 and originally named IntraLens Vision, Inc., the company rebranded in 2005 to align with its focus on presbyopia treatments.
Afferent Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, founded in 2009. The company focuses on developing small molecule drugs aimed at treating chronic pain and various neurogenic disorders by targeting P2X3 receptors in nerve fibers. Its lead compound, AF-219, has completed two Phase 1 clinical studies and is designed to address conditions such as osteoarthritis, back pain, visceral pain, and neuropathy, as well as respiratory and urological issues.
Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory, and manufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by the state-of-the-art Atara T-cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California. For additional information about the company, please visit atarabio.com.
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. The company's most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrum efficacy in preclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. In addition, the company is pursuing preclinical programs in several other areas of interest to combat the global emergence of bacterial resistance.
Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. They have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, in order to revolutionize the traditional glaucoma treatment and management paradigm. They launched the iStent®, their first MIGS device, in the United States in 2012. They are leveraging their platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. They believe the iStent® is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, they completed an initial public offering and their shares are now traded on the New York Stock Exchange under the ticker symbol “GKOS”. The company was founded in 1998 and is based in San Clemente, California.
Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for rare seizure disorders and neuropsychiatric conditions. The company's primary product candidate, ganaxolone, is an allosteric modulator of GABAA receptors, designed for both intravenous and oral administration for various patient populations. It aims to address multiple indications, including status epilepticus, cyclin dependent kinase-like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, postpartum depression, and treatment-resistant depression. Marinus Pharmaceuticals collaborates with NovaMedica and has license agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals to advance its research and therapeutic offerings. Founded in 2003, the company is headquartered in Radnor, Pennsylvania.
Evofem Biosciences is a biopharmaceutical company focused on women's sexual and reproductive health. The company has developed Phexxi, a hormone-free vaginal gel that is the first of its kind approved in the United States for the prevention of pregnancy. Additionally, Evofem is working on EVO100, a vaginal pH regulator designed to prevent the transmission of Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. Headquartered in San Diego, California, Evofem aims to address unmet needs in the field of women’s health through innovative products.
Neothetics, Inc. was a clinical-stage specialty pharmaceutical company focused on developing therapeutics for the aesthetic market. Founded in 2007 and based in San Diego, California, the company aimed to address cosmetic concerns through innovative treatments. Its primary product candidate, LIPO-202, was an injectable formulation designed to reduce localized fat deposits, specifically targeting submental fat under the chin and central abdominal bulging in non-obese individuals. In January 2018, Neothetics was acquired by Evofem Biosciences in a reverse merger transaction, marking a significant shift in its business trajectory. The company was previously known as Lipothera, Inc. before rebranding in August 2014.
Regado Biosciences is a biopharmaceutical company focused on the discovery and development of aptamer-based therapeutics, particularly those that offer antidote-controlled solutions for managing anticoagulation. Founded in 2001 and headquartered in Durham, North Carolina, the company has developed REG1, a treatment for patients with acute coronary syndrome undergoing procedures such as coronary artery bypass grafting and percutaneous coronary intervention. Regado's innovative approach involves the use of antithrombotic aptamers combined with controlling agents, which target both arterial and venous thrombosis, aiming to enhance patient safety and treatment efficacy.
Kona Medical, Inc. is a medical technology company founded in 2009 and based in Issaquah, Washington. It specializes in the development of a non-invasive ultrasound-based therapy system aimed at treating hypertension, particularly in patients with drug-resistant hypertension. The company's flagship product, Surround Sound, utilizes ultrasound imaging to precisely guide the application of focused ultrasound energy for renal denervation, targeting the nerves connected to the kidneys to help regulate blood pressure. By offering a less invasive alternative to traditional treatments, Kona Medical seeks to address the health risks associated with high blood pressure while improving patient outcomes through advanced therapeutic techniques.
Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with a number of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health.
RightCare Solutions employs evidence-based technology to help healthcare providers optimize their discharge planning process. With their proprietary Discharge Decision Support System, D2S2, hospitals, insurers, and homecare agencies improve the quality of care for patients while alleviating the devastating toll that 30-day re-admissions exact on the healthcare system. It was founded in 2011 and headquartered in Horsham, Pennsylvania.
Cotera, Inc. specializes in the design and development of orthopedic implants aimed at treating knee osteoarthritis. Founded in 2011 and located in Menlo Park, California, the company has introduced innovative devices, including the Latella device, which is surgically attached to the femur to alleviate medial knee pain associated with osteoarthritis. This implant not only provides immediate relief but is also designed for easy removal, preserving future treatment options for patients. Cotera's focus is on improving the quality of life for individuals suffering from joint pain through advanced orthopedic solutions.
Private Equity Round in 2012
Veracyte, Inc. is a genomic diagnostics company based in South San Francisco, California, that specializes in improving patient care through advanced genomic testing. The company offers a range of diagnostic products, including the Afirma Genomic Sequencing Classifier for thyroid cancer, the Percepta Genomic Sequencing Classifier for lung cancer, the Envisia Genomic Classifier for idiopathic pulmonary fibrosis, and the Prosigna Breast Cancer Prognostic Gene Signature Assay. These tests help identify benign conditions, differentiate diseases, and assess cancer recurrence risk, thereby reducing the need for invasive procedures and expediting treatment decisions. Veracyte collaborates with various organizations, including Johnson & Johnson, to enhance the development and commercialization of innovative diagnostic tests. With a commitment to leveraging genomic science and technology, Veracyte aims to deliver effective solutions for patients and healthcare providers globally.
Tandem Diabetes Care, Inc. is a medical device company that specializes in designing, developing, and marketing insulin delivery systems for individuals with insulin-dependent diabetes. Based in San Diego, California, the company’s flagship product is the t:slim X2 insulin delivery system, which includes a pump, a 300-unit disposable insulin cartridge, and an infusion set. The t:slim X2 is available with various advanced technologies, such as Basal-IQ and Control-IQ, and features like G5 integration. In addition to its insulin pumps, Tandem offers the t:connect web-based data management application and the Sugarmate mobile app to assist users in managing their diabetes. The company has also entered into a development and commercialization agreement with Dexcom, Inc. Tandem Diabetes Care has expanded its product line to include the smaller Mobi pump and is working on a tubeless insulin delivery system. The majority of its revenue comes from the U.S., with a smaller portion from other developed markets.
ROX Medical is an early phase medical device company that is pioneering an innovative treatment for Chronic Obstructive Pulmonary Disease (COPD). Their therapy is intended to improve the delivery of oxygen to tissue to treat hypoxemia in COPD patients via the creation of a therapeutic fistula.
Ocunexus Therapeutics is a biopharmaceutical company that develops therapeutics for unmet clinical needs in ophthalmology. The company specializes in developing highly differentiated drug candidates based upon a novel mechanism of action called “Gap Junction Channel Modulation.” It has developed treatments for multiple front- and back-of-the-eye diseases and disorders that would potentially alter the standard of care. In addition, the company's technologies are expected to be transferable to other acute and chronic disease indications. Ocunexus is formerly known as CoDa Therapeutics, a pharmaceutical company focused on the development and commercialization of wound care therapeutics based on gap junction modulation. The company is based in San Diego, California.
Obalon Therapeutics, Inc. is a medical device company based in Carlsbad, California, that specializes in developing and commercializing innovative solutions for obesity treatment. The company is known for its Obalon Balloon System, which includes a swallowable capsule containing an inflatable balloon, a navigation console for tracking balloon placement, a semi-automated inflation device, and a disposable gas canister. This system aims to assist patients in achieving weight loss through a non-surgical approach. Founded in 2008, Obalon emphasizes collaboration with clinicians and a commitment to rigorous testing to ensure safety and performance in its products. As of early 2020, the company operated three retail treatment centers in California, reflecting its focus on providing accessible solutions for individuals struggling with obesity.
Bionano Genomics is a biotechnology company that specializes in genome mapping and analysis, focusing on structural variation detection in DNA. The company develops the Saphyr system, which offers ultra-sensitive and specific detection of structural variations—such as insertions, deletions, inversions, and translocations—linked to various genetic disorders, including cancer. Utilizing optical genome mapping technology, the Saphyr system enables the direct visualization of long DNA molecules and their structural variations without the need for sequencing. This capability is crucial for researchers and clinicians aiming to gain insights into disease mechanisms and genetic disorders, ultimately aiding in the development of personalized treatment strategies. Bionano Genomics markets its products primarily to academic and governmental laboratories, as well as pharmaceutical and biotechnology companies across multiple regions, including North America, Europe, and Asia. Headquartered in San Diego, California, the company was founded in 2003 and was previously known as BioNano Genomics, Inc. until its name change in July 2018.
Adynxx is a clinical-stage biopharmaceutical company based in San Francisco, California, focused on developing innovative pain management therapies. Established in 2007, the company is working on a new class of therapeutics known as transcription factor decoys to address unmet medical needs in pain and inflammation treatment. Its pipeline features AYX1, a drug candidate aimed at preventing acute post-operative pain and its progression to chronic pain, and brivoligide, currently in Phase 2 trials for postoperative pain management. Additionally, Adynxx is developing AYX2, a pre-clinical candidate designed to treat chronic pain syndromes, including inflammatory and neuropathic pain.
Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, particularly vertebral compression fractures and degenerative disc diseases. Its key products include the Kiva treatment system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for pathological vertebral compression fractures. Additionally, the company offers the Luna 3D expandable interbody fusion system, suitable for various surgical approaches. Headquartered in Santa Clara, California, Benvenue Medical serves customers across the United States, Canada, Belgium, France, and Germany. Founded in 2004, the company is committed to providing innovative solutions that enhance patient outcomes and restore spinal alignment.